AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases.
Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease.
The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease.
In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019.
Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Country | United States |
IPO Date | May 3, 2000 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 8 |
CEO | N. Scott Fine |
Contact Details
Address: 6714 NW 16th Street Gainesville, Florida United States | |
Website | https://www.cyclotherapeutics.com |
Stock Details
Ticker Symbol | CYTH |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000922247 |
CUSIP Number | 550241103 |
ISIN Number | US23254X2018 |
Employer ID | 59-3029743 |
SIC Code | 2860 |
Key Executives
Name | Position |
---|---|
N. Scott Fine | Chief Executive Officer & Director |
Dr. Jeffrey L. Tate Ph.D. | Chief Operating Officer, Chief Quality Officer & Director |
Joshua M. Fine | Chief Financial Officer & Secretary |
C. E Strattan | Founder & Director |
Dr. Karen Mullen FFPM | Interim Chief Medical Officer |
Lori McKenna | Global Head of Patient Advocacy |
Michael Eric Lisjak | Senior Vice President of Business Development & Chief Regulatory Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 13, 2025 | 4 | Filing |
Jan 13, 2025 | 8-K | Current Report |
Jan 03, 2025 | 8-K | Current Report |
Dec 23, 2024 | 8-K | Current Report |
Dec 18, 2024 | 10-K/A | [Amend] Annual Report |
Dec 05, 2024 | 8-K | Current Report |
Nov 26, 2024 | 10-K/A | [Amend] Annual Report |
Nov 18, 2024 | 4 | Filing |
Nov 18, 2024 | 4 | Filing |
Nov 18, 2024 | 4 | Filing |